Efficacy and safety of tanshinone IIA in combination with mesalazine in the treatment of ulcerative colitis: a Systematic review and meta-analysis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100968547 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-230X (Electronic) Linking ISSN: 1471230X NLM ISO Abbreviation: BMC Gastroenterol Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2001-
    • Subject Terms:
      Colitis, Ulcerative*/drug therapy ; Abietanes*/therapeutic use ; Mesalamine*/therapeutic use ; Drug Therapy, Combination* ; Anti-Inflammatory Agents, Non-Steroidal*/therapeutic use ; Anti-Inflammatory Agents, Non-Steroidal*/administration & dosage; Humans ; Treatment Outcome ; Randomized Controlled Trials as Topic ; Tumor Necrosis Factor-alpha/antagonists & inhibitors
    • Abstract:
      Background: Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by relapsing inflammation of the colon. Tanshinone IIA, a compound derived from traditional Chinese medicine, has demonstrated anti-inflammatory properties and may enhance treatment outcomes when combined with mesalazine. This study aims to determine the overall response rate of Tanshinone IIA in combination with mesalazine for the treatment of UC.
      Methods: We reviewed articles from the establishment of the databases until April 2023 in the PubMed, Embase, Cochrane Library, CNKI, Wanfang, CQVIP, and CBM databases. They included a randomized controlled trial in which the intervention group was given tanshinone IIA plus mesalazine (T + M), while the comparative group was given only mesalazine (M). We removed duplicates or similar papers; papers with no available full text or incomplete data; animal research; and review and systematic review articles. STATA 15.1 was used to analyze the data.
      Results: The perceived total effectiveness rate of T + M was found to be higher than M and the difference was found to be significant (P = 0.000). Additionally, pooled results show that TNF-α (P = 0.000) and CRP (P = 0.000) levels in the T + M group were all significantly lower than that in the M group. Furthermore, MHC-II expression in the T + M group was minors compared to that of the M group (P = 0.001). However, there was no significant difference in the incidence of adverse events between the T + M and M groups (P = 0.700).
      Conclusion: This meta-analysis demonstrates that combining tanshinone IIA with mesalazine significantly enhances the overall treatment efficacy for ulcerative colitis compared to mesalazine alone. Tanshinone IIA also exhibits anti-inflammatory effects by reducing TNF-α, CRP levels, and MHC-II expression without notably increasing adverse events. Despite some limitations, these findings suggest that tanshinone IIA can be a promising adjunctive therapy for ulcerative colitis. Further large-scale, multi-center studies are needed to confirm these results and establish the long-term safety and effectiveness of this combination therapy.
      Competing Interests: Declarations Ethics approval and consent to participate Not applicable. Consent for publication All of the authors are aware of and agree to the content of the paper and their being listed as a co-author of the paper. Competing interests The authors declare no competing interests.
      (© 2024. The Author(s).)
    • References:
      Ann Intern Med. 2009 Aug 18;151(4):264-9, W64. (PMID: 19622511)
      Eur J Pharm Biopharm. 2021 Oct;167:89-103. (PMID: 34329709)
      Lancet Gastroenterol Hepatol. 2023 Jun;8(6):579-590. (PMID: 36933563)
      Perm J. 2015 Winter;19(1):52-7. (PMID: 25663206)
      Digestion. 2023;104(1):58-65. (PMID: 36366816)
      World J Gastroenterol. 2014 Nov 28;20(44):16389-97. (PMID: 25469007)
      J Crohns Colitis. 2020 Sep 16;14(9):1274-1281. (PMID: 32179906)
      Biomol Ther (Seoul). 2017 Nov 1;25(6):599-608. (PMID: 28173640)
      Immunotherapy. 2023 Jul;15(10):713-727. (PMID: 37129377)
      Gut Pathog. 2010 Dec 17;2(1):21. (PMID: 21167058)
      Brain Res. 2010 Mar 19;1321:143-51. (PMID: 20043889)
      Biochem Biophys Res Commun. 2010 Sep 3;399(4):613-6. (PMID: 20682292)
      Mod Pathol. 2010 Dec;23(12):1624-33. (PMID: 20802465)
      Curr Opin Immunol. 2023 Jun;82:102325. (PMID: 37075597)
      Atherosclerosis. 2013 Sep;230(1):148-56. (PMID: 23958267)
      Discov Med. 2023 Feb 1;35(174):1-10. (PMID: 37024436)
      Can J Gastroenterol. 2013 Mar;27(3):e18-24. (PMID: 23516681)
      Drug Des Devel Ther. 2013 Apr 08;7:289-96. (PMID: 23630414)
      Clin Gastroenterol Hepatol. 2024 Feb;22(2):243-251.e5. (PMID: 36858143)
      Am J Chin Med. 2022;50(7):1781-1798. (PMID: 35950375)
      Physiol Genomics. 2011 Jan 7;43(1):43-56. (PMID: 20923862)
      Cureus. 2024 Jun 2;16(6):e61547. (PMID: 38835557)
      Int J Prev Med. 2012 Nov;3(11):749-63. (PMID: 23189226)
      Orthod Craniofac Res. 2023 Feb;26(1):13-26. (PMID: 35545921)
      Expert Rev Gastroenterol Hepatol. 2019 Jun;13(6):557-561. (PMID: 30947569)
      Environ Sci Pollut Res Int. 2023 May;30(25):66486-66493. (PMID: 37118388)
    • Grant Information:
      2022KY915 Medical Health Science and Technology Project of Zhejiang Provincial Health Commission; 81774070 National Natural Science Foundation of China
    • Contributed Indexing:
      Keywords: Efficacy and safety; Mesalazine; Systematic review and meta-analysis; Tanshinone IIA; Ulcerative colitis
    • Accession Number:
      0 (Abietanes)
      4Q81I59GXC (Mesalamine)
      03UUH3J385 (tanshinone)
      0 (Anti-Inflammatory Agents, Non-Steroidal)
      0 (Tumor Necrosis Factor-alpha)
    • Publication Date:
      Date Created: 20241116 Date Completed: 20241116 Latest Revision: 20241122
    • Publication Date:
      20241123
    • Accession Number:
      PMC11566517
    • Accession Number:
      10.1186/s12876-024-03496-1
    • Accession Number:
      39548391